test

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Conditions

Malignant Melanoma

What is the purpose of this trial?

The purpose of this study is to determine the safety and tolerability of treatment with BMS-936558 (MDX-1106) in combination with Ipilimumab (BMS-734016) when given at the same time or as a sequenced regimen in subjects with unresectable Stage III or Stage IV malignant melanoma (MEL)


Participation Guidelines

Age:
18 Years and older
Gender:
Both

Click here for detailed information about who can participate in this trial.

Sponsor:
Bristol-Myers Squibb
Medarex
Ono Pharma USA Inc
Dates:
January 2009
Last Updated:
April 12, 2013
Study HIC#:
0908005564

Clinicaltrials.gov ID: NCT01024231